TABLE 1

Anthropometric, clinical, and laboratory data in NAFLD patients, type 2 diabetic patients, and control subjects

NAFLD patientsType 2 diabetic patientsControl subjects
n301010
Sex (M/F)24/68/28/2
Age (years)41 ± 11 (24–64)*56 ± 8 (45–67)48 ± 14 (26–60)
Weight (kg)81 ± 10 (65–96)84 ± 10 (66–105)73 ± 11 (57–94)
BMI (kg/m2)27 ± 2 (23–29)29 ± 4 (24–37)24 ± 2 (21–28)
Waist circumference (cm)100 ± 8 (87–115)98 ± 8 (77–109)85 ± 12 (73–100)
Hip circumference (cm)106 ± 6 (94–117)109 ± 10 (100–135)101 ± 6 (90–109)
Waist-to-hip ratio0.94 ± 0.06 (0.80-1.08)0.92 ± 0.09 (0.71–1.04)0.84 ± 0.10 (0.71–0.95)
Fasting glucose (mmol/l)5.2 ± 0.5 (4.4–6.0)*6.3 ± 0.4 (5.7–7.1)5.0 ± 0.4 (4.4–5.7)
120-min OGTT glucose (mmol/l)5.7 ± 0.9 (4.1–7.2)Not determined5.9 ± 0.8 (4.7–7.2)
Total cholesterol (mmol/l)5.5 ± 1.1 (3.9–9.1)5.0 ± 0.8 (4.0–6.5)4.9 ± 0.9 (3.4–5.9)
HDL cholesterol (mmol/l)1.1 ± 0.3 (0.7–2.1)1.0 ± 0.2 (0.7–1.4)1.5 ± 0.3 (1.0–2.1)
Triglycerides (mmol/l)2.3 ± 1.0 (0.9–4.9)2.3 ± 1.2 (0.7–4.3)1.1 ± 0.4 (0.6–1.6)
Uric acid (μmol/l)349 ± 64 (208–476)358 ± 73 (227–479)235 ± 59 (156–329)
Fasting insulin (pmol/l)124 ± 58 (43–265)143 ± 59 (86–258)44 ± 20 (14–79)
Fasting C-peptide (pmol/ml)1,080 ± 236 (719–1,548)900 ± 298 (525–1,548)677 ± 200 (498–1,161)
AST (units/l)42 ± 16 (25–98)*19 ± 7 (12–29)16 ± 5 (10–22)
ALT (units/l)90 ± 40 (44–203)*29 ± 10 (15–44)22 ± 7 (12–33)
  • Data are means ± SD (range). Normal AST and ALT values <40 units/l.

  • *

    * P < 0.005 vs. patients with type 2 diabetes;

  • P < 0.005 vs. control subjects.